Takashi Soyano, Atsunori Yorozu, Nana Natsume, Takashi Hanada, Yutaka Shiraishi, Kazuhito Toya, Shiro Saito. Time to achieve a prostate-specific antigen nadir of ≤0.2 ng/mL and related factors after permanent prostate brachytherapy. Brachytherapy. 2021. 20. 1. 29-37
Shinya Sutani, Atsunori Yorozu, Kazuhito Toya, Yutaka Shiraishi, Toru Nishiyama, Yasuto Yagi, Ken Nakamura, Shiro Saito. Effect of adding androgen deprivation therapy to permanent iodine-125 implantation with or without external beam radiation therapy on the outcomes in patients with intermediate-risk prostate cancer: A propensity score-matched analysis. Brachytherapy. 2021. 20. 1. 10-18
Tatsuo Masubuchi, Yosuke Kitani, Chihiro Fushimi, Daisuke Kawakita, Hideaki Takahashi, Etsuro Takeishi, Tetsuharu Kaneko, Chihiro Kanno, Morio Yamazaki, Junpei Tanaka, et al. Low-dose cisplatin administration through the superficial temporal artery combined with definitive radiotherapy for maxillary sinus squamous cell carcinoma. Journal of Clinical Oncology. 2020. 38. 15_suppl. e18562-e18562
Shinya Sutani, Atsunori Yorozu, Kazuhito Toya, Toru Nishiyama, Choichiro Ozu, Yasuto Yagi, Ken Nakamura, Shiro Saito. Whole-gland salvage treatment for recurrent prostate cancer after initial definitive radiotherapy: A case series of 125I brachytherapy and robot-assisted radical prostatectomy. Journal of contemporary brachytherapy. 2019. 11. 3. 201-206
Tomoki Tanaka, Atsunori Yorozu, Shinya Sutani, Yasuto Yagi, Toru Nishiyama, Yutaka Shiraishi, Toshio Ohashi, Takashi Hanada, Shiro Saito, Kazuhito Toya, et al. Predictive factors of long-term rectal toxicity following permanent iodine-125 prostate brachytherapy with or without supplemental external beam radiation therapy in 2216 patients. Brachytherapy. 2018. 17. 5. 799-807